Sangart reports positive Phase IIa data for novel oxygen therapeutic agent MP4OX in trauma patients
Tuesday, August 31, 2010 - 07:42
in Health & Medicine
Sangart, Inc., today announced positive results from its Phase IIa proof-of-concept study of MP4OX (oxygenated pegylated hemoglobin) in severely injured trauma patients with hemorrhagic shock causing...
